- Trials with a EudraCT protocol (572)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
572 result(s) found for: Triple test.
Displaying page 1 of 29.
EudraCT Number: 2011-001635-23 | Sponsor Protocol Number: TMC114IFD3003 | Start Date*: 2012-01-17 | |||||||||||
Sponsor Name:Janssen Cilag International N.V. | |||||||||||||
Full Title: PROTEAse inhibitor (DRV/rtv) in mono- or triple therapy in suppressed HIV-1 infected subjects | |||||||||||||
Medical condition: HIV-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) IE (Completed) DE (Completed) ES (Completed) AT (Completed) HU (Completed) DK (Completed) IT (Completed) SE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014430-25 | Sponsor Protocol Number: SAI-CDV-2009-01 | Start Date*: 2009-12-17 |
Sponsor Name:Sociedad Andaluza de Enfermedades Infecciosas SAEI | ||
Full Title: Ensayo clínico abierto, aleatorizado, para comparar la calidad de vida de los pacientes VIH+ que inician monoterapia con comprimidos de LPV/r vs triple terapia que contengan un IP potenciado | ||
Medical condition: Pacientes infectadis por VIH-1 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001463-75 | Sponsor Protocol Number: ICO-2019-04 | Start Date*: 2020-02-03 | |||||||||||
Sponsor Name:INSTITUT DE CANCEROLOGIE DE L'OUEST | |||||||||||||
Full Title: Pilot Feasibility Study: Inflammation and presence of M2 macrophages explorations with[18F]-DPA-714 PET/CT in Triple Negative breast cancers | |||||||||||||
Medical condition: Patients with Triple Negative Breast Cancer prior to surgical treatment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000774-70 | Sponsor Protocol Number: CVEA489A2302 | Start Date*: 2006-09-04 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: An 8-week, multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the combination of valsartan/HCTZ/amlodipine compared to valsartan/HCTZ, valsartan/amlo... | ||
Medical condition: Hypertension | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) SE (Completed) DK (Completed) PT (Completed) GR (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-001323-37 | Sponsor Protocol Number: SPA-378-05-40 | Start Date*: 2004-11-29 |
Sponsor Name:H. 12 de Octubre [...] | ||
Full Title: Phase IV-III, open-label, randomized, comparative study, to evaluate the safety and efficacy of the nucleoside supression of a triple therapy based on lopinavir-ritonavir vs. continuous triple ther... | ||
Medical condition: Infection by Human inmunideficiency virus | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-002006-30 | Sponsor Protocol Number: 02RH001 | Start Date*: 2004-11-17 |
Sponsor Name:North Glasgow NHS Trust | ||
Full Title: Triple therapy in early active rheumatoid arthritis | ||
Medical condition: Rheumatoid arthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-003648-97 | Sponsor Protocol Number: CLI-06001AA1-05 | Start Date*: 2021-05-17 | |||||||||||
Sponsor Name:Chiesi Farmaceutici S.p.A. | |||||||||||||
Full Title: A 52-week, randomized, double-blind, double-dummy, placebo- and active- controlled (Roflumilast, Daliresp® 500μg), parallel group, study to evaluate the efficacy and safety of two doses of CHF6001 ... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) SK (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) EE (Trial now transitioned) LV (Trial now transitioned) ES (Ongoing) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005200-19 | Sponsor Protocol Number: I-CONIC | Start Date*: 2022-05-09 |
Sponsor Name:Västra Götalandsregionen/Onkologiska kliniken | ||
Full Title: Use of Imatinib to convert triple negative breast cancer into ER-positive breast cancer - "I-CONIC" | ||
Medical condition: Early Triple Negative Breast Cancer planned for surgery. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2014-003790-41 | Sponsor Protocol Number: JAN12006-01 | Start Date*: 2015-05-11 |
Sponsor Name:Spherium Biomed | ||
Full Title: Randomised, double-blinded, placebo and active comparator controlled exploratory clinical trial to assess the efficacy and safety of a triple combination of Ibuprofen, magnesium and ascorbic acid ... | ||
Medical condition: Temporomandibular joint dysfunction syndrome. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003805-71 | Sponsor Protocol Number: ICO-2020-25 | Start Date*: 2021-03-29 | |||||||||||
Sponsor Name:INSTITUT DE CANCEROLOGIE DE L'OUEST | |||||||||||||
Full Title: Prospective phase II pilot study, assessing imaging performance of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT in metastatic triple negative breast cancer patients OPALESCENCE: zircOn P... | |||||||||||||
Medical condition: Patients with Triple Negative Breast Cancer recurrence | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003167-38 | Sponsor Protocol Number: NL50643.09r.r4 | Start Date*: 2015-04-28 |
Sponsor Name:Radboudumc | ||
Full Title: 68Ga-NODAGA-exendin-4 PET/CT in patients with AHH - a prospective comparative evaluation of preoperative imaging Under the FP7 project Betacure (602812); Personalized diagnosis and treatment of hy... | ||
Medical condition: Adult endogenous hyperinsulinemic hypoglycemia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-000677-23 | Sponsor Protocol Number: CLCL161A2201 | Start Date*: 2012-10-24 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A Phase II, multi-center, open-label, neoadjuvant, randomized study of weekly paclitaxel with or without LCL161 in patients with triple negative breast cancer | ||
Medical condition: Triple negative breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: GB (Completed) ES (Completed) IE (Completed) IT (Completed) BE (Completed) CZ (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-004810-41 | Sponsor Protocol Number: MV28073 | Start Date*: 2012-04-18 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: An international, multicenter, open-label study evaluating sustained virological response and safety with Boceprevir in triple combination therapy with Peginterferon alfa-2a (40KD) and Ribavirin in... | |||||||||||||
Medical condition: Genotype 1 CHC virus infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) HU (Completed) ES (Completed) PL (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001805-40 | Sponsor Protocol Number: TRICORDA | Start Date*: 2023-03-27 |
Sponsor Name:Hospital Universitario Lucus Augusti | ||
Full Title: Increase in inhaled corticosteroid dose vs triple therapy in T2-high asthma patients who remain uncontrolled with medium dose inhaled corticosteroids/long-acting β2 adrenergic combination: a real-l... | ||
Medical condition: Asthma is an important global health problem that affects people of all ages . Despite effective and safe therapeutic options, up to 75% of patients with asthma remain uncontrolled . It remains to ... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-001080-23 | Sponsor Protocol Number: R+OCA | Start Date*: 2014-05-26 | |||||||||||
Sponsor Name:Javier P. Gisbert | |||||||||||||
Full Title: Rifaximin associated with the classic triple therapy (inhibitor proton pump, amoxicillin and clarithromycin) for eradication of Helicobacter pylori infection | |||||||||||||
Medical condition: Helicobacter pylori infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-007758-36 | Sponsor Protocol Number: P/2008/78 | Start Date*: 2009-04-09 |
Sponsor Name:Centre Hospitalier Universitaire de Besançon | ||
Full Title: Intérêt du rémifentanil dans l’anesthésie pour triple endoscopie en ventilation spontanée : étude randomisée contrôlée contre placebo Etude ENDOTANIL | ||
Medical condition: Triple endoscopie pour suspicion de néoplasie pharyngolaryngée | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-001962-27 | Sponsor Protocol Number: ACT14884 | Start Date*: 2016-12-07 | |||||||||||
Sponsor Name:Sanofi-aventis recherche & développement | |||||||||||||
Full Title: Open-label Phase 2 study evaluating efficacy and safety of SAR566658 treatment in patients with CA6 positive metastatic Triple Negative Breast Cancer | |||||||||||||
Medical condition: Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) BE (Completed) ES (Prematurely Ended) FR (Completed) CZ (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002435-15 | Sponsor Protocol Number: FiHM003 | Start Date*: 2017-08-10 |
Sponsor Name:Fundación de Investigación HM Hospitales | ||
Full Title: Pilot study to assess physical exercise intervention in neoadjuvant treatment with nab-paclitaxel in patients with triple negative breast cancer | ||
Medical condition: Supervised exercise regimen given during neoadjuvant chemotherapy for triple negative breast cancer patients. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003666-40 | Sponsor Protocol Number: CLI-06001AA1-04 | Start Date*: 2021-05-05 | |||||||||||
Sponsor Name:Chiesi Farmaceutici S.p.A. | |||||||||||||
Full Title: A 52-week, randomized, double-blind, placebo-controlled, parallel-group, study to evaluate the efficacy and safety of two doses of CHF6001 DPI add-on to maintenance triple therapy in subjects with ... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) SK (Trial now transitioned) AT (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) PL (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001150-33 | Sponsor Protocol Number: 207609 | Start Date*: 2018-05-29 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A Phase IV, 12-week, randomised, double-blind, triple dummy study to compare single inhaler triple therapy, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) with multiple inhaler therapy (b... | |||||||||||||
Medical condition: Chronic obstructive pulmonary disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) PT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
